Skip to main content

Study shows cannabis use during pregnancy may be linked to delays in growth and development in infants

New HealthPartners Institute research serves as a caution for expecting moms who self-medicate with marijuana to control nausea during pregnancy


January 10, 2020


BLOOMINGTON, Minn. – As more states consider marijuana legalization, new research published in the Journal of Perinatology describes how cannabis exposures during pregnancy could affect infants’ growth and development.

Researchers at HealthPartners Institute, University of Iowa and the University of Minnesota analyzed data on 3,435 women receiving prenatal care in the HealthPartners care system over a 21-month period. Urine testing, a routine part of pregnancy care in the care system, showed 283 women had cannabis in their system while pregnant.

According to the study, babies born to women who had cannabis in their system during pregnancy were more likely to have their birth weight for age at or below the 10th percentile, also known as small for gestational age. Additionally, 9.1 percent of the babies exposed to cannabis during pregnancy had an abnormal developmental screening at 12 months of age, compared to 3.6 percent of babies who were not exposed to cannabis during pregnancy.

“This research adds to the growing body of literature on the effects of prenatal use of marijuana on fetal and child development,” says Dr. Paul Romitti, professor of epidemiology at the University of Iowa College of Public Health and senior author of the study. “With marijuana use being legalized in more states, the potential for use among women who are pregnant or not aware that they are pregnant has increased.”

Although nationwide data show about 5 percent of women self-report using marijuana during pregnancy, over 8 percent of women the researchers studied had a positive urine screen for cannabis during a prenatal visit. According to the researchers, this could indicate that self-reported figures may not capture the full scope fetal cannabis exposures. With the increasing access to cannabis across the nation, some reports suggest that women are using the drug to self-medicate pregnancy-related nausea.

Elyse Kharbanda, MD, senior investigator at HealthPartners Institute and lead author of the study, says that it’s possible that women may use cannabis when they don’t realize they’re pregnant, they don’t realize how long cannabis can stay in their system, or they may use and don’t report this on surveys due to fear of stigma.

The study was funded by a grant awarded from the Centers for Disease Control and Prevention to Dr. Romitti at the University of Iowa.

About HealthPartners Institute

HealthPartners Institute is part of HealthPartners, the largest consumer-governed, non-profit health care organization in the nation with a mission to improve health and well-being in partnership with members, patients and the community. HealthPartners Institute supports this mission through research, education and practice. The Institute annually conducts 400+ research studies and trains 700+ medical residents and fellows and 1,200+ medical and advanced practice students. Its integration with HealthPartners’ hospitals, clinics and health plan strengthens the Institute’s ability to discover and develop evidence-based solutions and translate them into practice. Based in Minneapolis, the Institute’s work impacts care, health and well-being across the region and nation as well as internationally. Visit healthpartnersinstitute.org for more information.

Back to top